Form 4: Agios Pharmaceuticals Director David Scadden Reports Stock Transactions
SEC Form 4 Filing
Director David Scadden reports the vesting and subsequent disposal of restricted stock units in Agios Pharmaceuticals.
Summary
- On June 13, 2024, David Scadden, a director of Agios Pharmaceuticals, reported transactions involving the company's common stock.
- Specifically, 3,388 restricted stock units vested, each representing a contingent right to receive one share of Agios' common stock.
- These restricted stock units were granted on June 13, 2023, and vested in full on June 13, 2024.
- Following the vesting, Scadden disposed of 3,388 shares of common stock.
- After these transactions, Scadden beneficially owns 15,483 shares of Agios Pharmaceuticals.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The disclosure provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| June 13, 2023 | Restricted stock units were granted. |
| June 13, 2024 | Restricted stock units vested and shares were disposed of. |
| June 17, 2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.